Accordingly, in 2021, the National Comprehensive Cancer Network Guidelines197 removed anthracycline-based therapy from the list of “preferred regimens” for the treatment of HER2+ early-stage breast cancer and into the category of regimens for use in certain situations. This evidence concerns the gene ERBB2 and breast cancer.